Lentigo maligna (LM) is an in situ lesion with a 2% to 50% risk of progression to LM melanoma.
1 Currently, surgery or radiotherapy is usually recommended as the primary treatment for LM. In the literature, the recurrence rates reported for radiotherapy range from 0% to 19%, with a mean recurrence rate of approximately 7%; in addition, radiotherapy carries the risk of causing chronic radiodermatitis or radiation-induced malignant neoplasm.
2 A margin-controlled excision using “slow Mohs” (rush permanent sections) and Mohs micrographic surgery has the lowest recurrence rate, perhaps as low as 3%.
3